Neurocrine ’s Ingrezza fails to meet primary endpoint in Phase II trial for Tourette syndrome

US-based biotechnology firm Neurocrine Biosciences ’ Ingrezza (valbenazine) has failed to meet the primary endpoint in its Phase II T-Force GREEN clinical trial to treat Tourette syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news